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ORIGINAL ARTICLE
Cervical cancer remains a key health problem
among women worldwide.1 In recent years, this
disease accounted for 6.5% of cancer deaths 
in Taiwanese women (http://www.doh.gov.tw/
statistic/). Though human papilloma viral infec-
tion appears to be an important factor in the 
etiology of cervical cancer, only a small fraction
of women harboring oncogenic human papilloma
virus in their lower genital tract will have pro-
gression to an invasive lesion.2 It is clear that a
human papilloma viral infection alone is insuffi-
cient for progression to a malignant phenotype.
Mounting evidence indicates that additional ge-
netic aberrations are required for the multistep
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process of tumor initiation and progression to an
invasive carcinoma.3 Delineation of these genetic
changes is critical for an understanding of the
molecular basis of cervical carcinogenesis, as well
as to discover markers that would identify pa-
tients at high risk for a poor outcome who would
benefit from aggressive adjuvant treatment.
The search for recurrent chromosomal aberra-
tions in cervical cancers has often been hampered
by technical difficulties in karyotype analysis.4
Comparative genomic hybridization (CGH) is a
molecular cytogenetic technique that allows com-
prehensive analysis of chromosomal imbalance
in an entire genome with a single test. Notably, 
it does not require cell culture and metaphase
preparation of the test samples.5 Identification of
characteristic chromosomal imbalances in a par-
ticular cancer would imply the presence of onco-
genes or tumor suppressor genes in these regions
of gain or loss, respectively. In previous CGH
studies of cervical cancer, many recurrent chro-
mosomal imbalances were reported, including
gains of 1q, 3q, 5p, 8q and X, and losses of 2q,
3p, 4p, 6q, 8p, 11q, 13q and 18q.6–15 However,
the prognostic significance of these recurrent chro-
mosomal imbalances7,9,13 as well as the recur-
rent loss of heterozygosity identified in different
allelotype studies16,17 often vary greatly and need
to be further elucidated.
Chromosomal imbalance pattern of cervical
cancer in Taiwanese women was reported in a
study of 20 cases of adenocarcinoma.18 For the
more common squamous cell carcinoma (SCC),
there has been no publication describing the
genome-wide pattern of chromosome imbalance
in Taiwan except for two reports of allelotype
analysis of the short arms of chromosomes 3 and
5.19–21 Moreover, due to recent improvements in
the Pap smear screening strategy, most Taiwanese
women with invasive cervical cancer are now di-
agnosed at an early stage. Surgery and radiation
therapy are relatively effective for controlling 
cervical cancer at its primary site. However, mor-
tality from this disease is usually caused by its
metastasis to lymph nodes and distant organs.22,23
In an attempt to provide CGH data for cervical
SCC in Taiwan, and to gain further insight into
the genetic markers that are significantly associ-
ated with lymph node metastasis (LNM) of this
disease, we performed CGH analysis of 30 con-
secutive cases of cervical SCC. The commonly re-
current chromosomal imbalances detected in this
study were further correlated with the pathologic
stage and the LNM status to evaluate their ability
to predict which tumors demonstrated high-risk
behavior.
Materials and Methods
Tumor specimens
Thirty consecutive cases of cervical SCC treated
by radical hysterectomy and lymphadenectomy
at Chi Mei Medical Center between January 2003
and September 2005 were collected for CGH
analysis. All samples were classified according to
the International Federation of Gynecology and
Obstetrics (FIGO) criteria. For the histological
identification of the pathologic lesions, the crite-
ria set by the World Health Organization and the
International Society of Gynecological Patholo-
gists were used. Twenty-four cases were classified
as stage IB and six as stage IIB. LNM was present
in nine cases (Table).
Under the guide of a hematoxylin-eosin stained
section, the paraffinized tissue of a tumor-enriched
region containing more than 80% carcinoma
cells, about 5 × 5 × 2 mm in volume, was selected.
The selected tissue was deparaffinized by treating
it twice with xylene at 55°C for 15 minutes each
time, followed by washes with absolute ethanol
and air-drying. The tissue was then incubated in
proteinase K solution (Sigma Co., St Louis, MO,
USA; with 0.5 mg/mL in 10 mM Tris, pH 7.8, 5 mM
EDTA, and 0.5% SDS) at 55°C overnight or longer,
if needed. DNA in suspension was purified using
a phenol/chloroform procedure, and resuspended
in 1X TE buffer.
CGH
The CGH procedure was modified from that de-
scribed by Kallioniemi et al5 and is provided in
CGH analysis of early stage cervical SCC
J Formos Med Assoc | 2007 • Vol 106 • No 11 895
K.F. Huang, et al
896 J Formos Med Assoc | 2007 • Vol 106 • No 11
Ta
b
le
.
Cl
in
ic
op
at
ho
lo
gi
c 
fe
at
ur
es
 a
nd
 c
om
pa
ra
tiv
e 
ge
no
m
ic
 h
yb
rid
iz
at
io
n 
fin
di
ng
s 
in
 3
0 
ca
se
s 
of
 e
ar
ly
 s
ta
ge
 c
er
vi
ca
l s
qu
am
ou
s 
ce
ll 
ca
rc
in
om
a
Ca
se
A
ge
LN
M
G
ai
n
Lo
ss
IB
 tu
m
or
s
1
45
N
D
20
6p
12
-p
23
, 6
q1
1-
q2
6,
 7
q3
1-
q3
5
2
54
N
D
3q
26
.1
-q
te
r
3p
14
-p
21
, 3
p2
3-
p2
5
3
60
N
D
Xq
13
-q
21
—
4
70
N
D
1q
22
-q
23
, 1
q3
1-
q4
3
8p
21
-p
23
5
71
N
D
1q
22
-q
24
, 1
q3
2,
 1
q4
1,
 3
q 
(3
q2
1-
q2
3,
 3
q2
6-
qt
er
), 
21
q1
1.
2
3p
13
-p
24
6
37
N
o
—
2q
36
-q
37
7
43
N
o
1q
23
, 1
q4
1-
q4
4,
 3
q2
3-
q2
4,
 3
q2
5,
 1
9q
13
.3
7p
13
-p
22
, X
q2
5-
q2
5
8
44
N
o
8q
22
-q
23
—
9
46
N
o
5p
, 1
3q
22
-q
31
3p
14
-p
24
, 4
q2
1-
q2
2,
 6
p2
1.
1-
p2
2,
 6
q1
6-
q2
5
10
46
N
o
1p
13
-q
22
, 3
q1
3.
1-
q2
1,
 5
q3
2-
q3
3,
 6
p1
2,
 9
p2
1-
pt
er
2q
36
-q
te
r, 
3p
14
-p
te
r, 
4p
12
-p
14
, 4
p1
6,
 4
q,
 1
1p
12
-p
15
, 1
1q
14
-q
25
11
51
N
o
—
2p
23
-p
24
, 2
p2
5-
pt
er
, 2
q3
7,
 6
p2
4,
 6
q2
2-
q2
4,
 1
1q
23
, 1
6q
23
12
56
N
o
2p
16
-p
21
, 5
p1
3-
p1
4,
 6
p1
1-
p1
2,
 1
5q
11
-q
13
—
13
56
N
o
1q
12
-q
23
, 1
q3
1-
q4
1,
 3
q2
5-
qt
er
 (3
q2
6.
3-
qt
er
), 
11
q2
1-
q2
2,
 1
7q
23
-q
24
10
q2
4-
q2
5,
 1
1q
24
-q
25
, 1
3q
12
-q
13
, 2
0p
1.
2-
p1
2
14
60
N
o
1q
31
22
q1
2-
q1
3
15
60
N
o
3q
21
-q
24
, 8
q1
2-
q2
1.
1,
 8
q2
1.
3,
 8
q2
4.
1-
q2
4.
3
1p
13
-p
21
, 1
p3
1-
p3
2,
 3
p2
4,
 1
0q
11
.2
, 1
0q
22
, 1
3q
21
16
60
N
o
3q
, 8
q 
(8
q2
4)
, 1
8q
11
.2
-q
12
, X
q1
3-
q2
1
2q
36
-q
te
r, 
6q
24
-q
25
, 1
1p
14
-p
te
r, 
11
q2
1-
q2
4
17
64
N
o
1q
21
-q
25
, 1
q3
1-
q3
2
—
18
67
N
o
15
q2
3-
q2
4
14
q1
1.
2-
q1
3
19
34
Ye
s
6p
11
.2
-p
12
—
20
44
Ye
s
1p
21
, 1
p2
2,
 1
p3
1,
 1
q2
5-
q3
1,
 3
q2
1-
q2
6.
3,
 8
q1
3,
 2
0p
11
.2
, 
7q
31
-q
32
, 1
0q
21
, 1
0q
24
, 1
1p
11
.2
-p
13
, 1
1q
22
-q
te
r, 
12
p1
2,
20
q1
1.
2-
q1
3.
2,
 2
1q
11
-q
22
12
q2
1-
q2
4.
1,
 1
3q
12
, 1
7p
11
.2
-p
13
, 1
7q
11
.2
-q
24
21
47
Ye
s
7p
11
-p
13
, X
p2
2.
1-
q2
1
—
22
49
Ye
s
1q
22
, 1
q2
4-
q3
1,
 2
p1
3-
p1
4,
 7
q1
1.
2,
 8
q2
2-
q2
4.
2,
 9
p2
2-
pt
er
, 1
3q
21
-q
34
1p
34
.3
, 1
p3
2-
p3
3,
 3
p2
1,
 6
q2
3-
q2
4,
 1
1p
14
-p
te
r, 
11
q1
4
23
50
Ye
s
3q
13
.1
-q
21
, 3
q2
3-
q2
6.
1,
 9
p1
1-
p1
3
2q
37
, 7
q3
1,
 1
1q
13
-q
te
r
24
62
Ye
s
3q
13
.1
-q
27
, 5
p1
3-
p1
5.
3,
 X
p1
1-
p2
1,
 X
p1
1-
p2
1
—
IIB
 tu
m
or
s
25
42
N
o
3q
, 6
p1
2,
 1
9q
13
.1
4p
13
26
45
N
o
6p
11
.2
-p
12
, 1
9q
13
.1
5q
23
, 1
7p
12
-p
13
27
63
N
o
1q
11
-q
41
, 2
q1
1.
2-
q1
3,
 8
p1
1-
q2
4,
 2
0p
12
-q
te
r
2q
37
, 6
p2
1.
2-
p2
1.
3,
 6
p2
2,
 6
q2
3,
 6
q2
4-
q2
5,
 9
q3
4,
 1
1q
13
-q
25
28
46
Ye
s
1p
35
-p
36
.1
, 3
q2
2-
q2
3,
 3
q2
6.
1-
q2
9
3p
14
-p
21
, 8
p1
2-
p2
1,
 1
0p
12
-p
13
, 1
0q
21
, 1
0q
22
, 1
0q
25
-q
26
, 
11
q1
4-
q2
2,
 1
1q
21
-q
22
, 1
5q
11
.2
-q
13
29
49
Ye
s
1q
11
-q
41
, 2
p1
2-
p2
3,
 3
q,
 5
p1
3-
pt
er
, 2
1q
11
.2
-q
22
3p
14
-p
26
, 4
p1
5.
1-
pt
er
, 9
p1
3-
pt
er
, 9
q3
2-
q3
4,
 1
1p
13
-p
te
r
30
60
Ye
s
3q
13
.3
-q
21
, 3
q2
6.
1-
q2
6.
3
3p
14
-p
21
, 6
q2
2-
q2
4,
 1
1q
14
-q
22
LN
M
 =
ly
m
ph
 n
od
e 
m
et
as
ta
si
s;
 N
D
 =
no
t d
on
e.
 C
hr
om
os
om
al
 r
eg
io
ns
 in
 b
ol
d
ex
hi
bi
te
d 
hi
gh
-le
ve
l a
m
pl
ifi
ca
tio
n.
CGH analysis of early stage cervical SCC
J Formos Med Assoc | 2007 • Vol 106 • No 11 897
detail elsewhere.24 Briefly, the metaphase slides
of normal females were kept in 95% ethanol at 
−20°C for at least 48 hours before processing for
CGH. DNA from a tumor and genomic DNA from
a healthy female donor (reference DNA) were di-
rectly labeled with fluorescein-12-dUTP or Texas
red-5-dUTP (NEN Life Science, Boston, MA, USA),
respectively, using the standard nick-translation
procedure. After precipitating the DNA in the pres-
ence of Cot1 DNA (Gibco BRL, Gaithersburg, MD,
USA), the labeled DNA mixture was hybridized
to metaphase spreads on a glass slide for 2–3
days. The slides were washed and then counter-
stained with 4,6-diamidino-2-phenylindole in an
antifading solution.
Image acquisition, processing, and evaluation
were performed using a fluorescence microscope
(Olympus BX51, Tokyo, Japan) equipped with a
Sensys charge-coupled device camera (Kodak KAF
1400 chip; Photometrics, Tucson, AZ, USA), which
was controlled using the CytoVision imaging sys-
tem (Applied Imaging, Santa Clara, CA, USA).
Chromosomal imbalances were determined based
on the calculation of standard reference intervals
using CytoVision High-Resolution CGH software,
by which we stringently defined DNA losses or
gains as significant whenever the tumor profile and
the standard reference interval profile at 99.5%
confidence did not overlap.25 However, short chro-
mosomal segments with a test-to-reference fluo-
rescence ratio > 1.5 were construed as showing
high-level amplification.
In each CGH experiment, a negative and posi-
tive control with a known chromosomal gain or
loss was also included. The negative control DNA
was isolated from an individual with a normal
karyotype. The positive control DNAs were pre-
pared from EBV-transformed lymphoblastoid cell
lines with either trisomy 21 (with a size of ap-
proximately 50 Mb) or an interstitial deletion of
2q23 (with a size of about 15 Mb).
Statistical analysis
For the analysis of the differences between two
comparison groups, we used Fisher’s exact two-
tailed test, the χ2 test, or the Mann–Whitney U test.
Values of p < 0.05 were considered statistically
significant.
Results
In each experiment, the green-to-red fluorescence
ratios of the negative control were all within the
standard reference interval of each chromosome.
The known chromosomal imbalances in the posi-
tive controls could also be unequivocally detected.
All tumor samples analyzed in this study revealed
chromosomal imbalance(s), ranging from 1 to 16
involved chromosome arms, with an average num-
ber of 5.1 arms per tumor. A higher average num-
ber of chromosomal imbalances were found in
stage IIB tumors (6.8, n = 6) than in stage IB tu-
mors (4.7, n = 24). Similarly, the average was also
higher in tumors with LNM (6.8, n = 9) than in
those without LNM (4.2, n = 21). However, with
respect to gain and loss, the frequencies were
very similar in stage IB (2.4 vs. 2.3) and stage IIB
(3.2 vs. 3.6) tumors, as well as in tumors with
(3.4 vs. 3.4) and without (2.1 vs. 2.1) LNM.
All chromosomal imbalance(s) observed in
this study are described in detail in the Table,
and also summarized in Figure 1. The commonly
recurrent chromosomal imbalances were gains
of 3q (n = 14, 46.7%), 1q (n = 11, 36.7%), and 8q
(n = 6, 20.0%) and losses of 11q (n = 10, 33.3%),
3p (n=9, 30.0%), 6q (n=7, 23.3%), and 2q (n=6,
20.0%). Comparison of these common chromo-
somal imbalances between stage IB and IIB tu-
mors, as well as tumors with and without LNM,
is depicted in Figure 2. There was no apparent
difference in the frequencies in the shortest over-
lapping region of these chromosomal imbal-
ances between stage IB and IIB tumors. However,
compared with tumors without LNM, those with
LNM were significantly more prevalent in the
loss of 11q14-q22 (5/9 vs. 3/21, p = 0.019) and in
gains of 3q11-q22 and 3q26-qter (6/9 vs. 5/21,
p = 0.026), as highlighted in the lower panel of
Figure 2. High-level amplifications were detected
at four chromosomal sites. However, the only re-
current amplification, located on 3q26-qter, was
K.F. Huang, et al
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present in two stage IB tumors without LNM.
These regions are indicated by the dark boxes in
Figures 1 and 2.
Discussion
All samples examined in this study, as well as in
most other CGH studies of cervical cancer,6,8–10,13,14
exhibited chromosomal imbalance(s). Some stud-
ies revealed that 10–20% of the stage IB cervical
SCC have no detectable chromosomal imbal-
ances.7,11,12 The trend of the chromosomal im-
balance number increasing along with the tumor
stage and LNM status are consistently observed
in this and other CGH studies of cervical cancer,6,7
confirming that genetic aberrations often accu-
mulate gradually during tumor progression. The
common chromosomal imbalances observed in
this study were gains of 3q, 1q and 8q, and losses
of 11q, 3p, 6q and 2q, a result consistent with
other similar studies.6,8–14 Notably, as depicted
in Figure 2, the results of the present study in-
dicate that the loss of 11q14-q22 and gains of
3q11-q22 and 3q26-qter were significantly more
prevalent in tumors with LNM than in those
without LNM.
Loss of 11q has been repeatedly identified as
a common chromosomal imbalance in cervical
SCC in other CGH studies9,10,12 and in most 
allelotype screening analyses.16,17 In other allelo-
type studies focused primarily on chromosome
11, the frequencies of loss of heterozygosity on
bands p12-p15, q12-13, q14-q22, and q23-q25
were estimated to be in the range of 28–33%,
34–40%, 43–62%, and 61–62%, respectively.26,27
Notably, the results of this study reveal that losses
at bands 11q14-q22, but not at bands 11q23-
qter, are significantly associated with LNM at an
early stage of cervical SCC. A similar finding was
also reported in another allelotype study,16 albeit
the only two microsatellite markers selected for
screening of 11q all mapped to 11q23.3. Further
studies are needed to more precisely define the
lost region on 11q, where tumor suppressor genes
important for controlling LNM in cervical cancer
would most likely be harbored, as may also be
true in many other human cancers.
Different study groups have recently focused on
11q13 and 11q23 in the search for the potential
1
6 7 8 9 10 11
13
19 20 21 22 Y X
14 15 16 17 18
12
2 4 53
Figure 1. Summary of all 
chromosomal imbalances identified
in 30 cases of early stage cervical
squamous cell carcinoma. The bars
on the right side and left sides 
of each chromosome ideogram 
indicate gains and losses, 
respectively.
CGH analysis of early stage cervical SCC
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tumor suppressor genes. Among the known genes
mapping to 11q13, Zainabadi et al excluded
SF3B2, BRMS1, RIN1 and RAB1B as tumor sup-
pressor genes in cervical carcinogenesis, but sug-
gested that PACS1 may have such potential.28 Many
genes mapped to 11q23, including PPP2R1B,
U90916 mRNA of unknown function, ZNF202,
LOH11CR2A, HSC71, and neurogranin, have also
been excluded from consideration as tumor sup-
pressor genes due to lack of evidence supporting
their tumorigenic potential.26 However, a recent
study found that the TSLC1 gene mapping to
11q23 often exhibits promoter hypermethyla-
tion in lesions of high-grade cervical intraepithe-
lial neoplasms (CIN; 35%, 7/20) and SCC (58%,
30/52), but not in lesions of low-grade CIN (0/9),
supporting its potential role as a tumor suppres-
sor gene.29 For the known genes mapping to
11q14-q22, no study elucidating their carcino-
genic potential has been conducted.
Gain of 3q was the most frequent aberration
(46.7%, 14/30) found in this study, comparable
to the overall detection rate of 47.8% (141/295)
found in many other CGH studies of cervical
SCC.6–14 Furthermore, our data also pointed out
that gains of 3q at bands 11-22 and 26-ter were
significantly more prevalent in tumors with LNM
than in those without LNM (p = 0.026). One other
study has described a similar finding.9 Ironically,
as depicted in Figure 2, we noticed that three
high-level amplifications on 3q were all found in
stage IB tumors without LNM. Moreover, it has
also been repeatedly demonstrated by others that
gain of 3q could be found occasionally in CIN
lesions, but were more prevalent in high-grade
CIN lesions and invasive SCC.8,12,30,31 When taken
1
Stage
2 3
11865
1
LNM
65
2 3
8 11
Figure 2. Comparison of the common chromosomal 
imbalances detected between pathological stage IB
(n = 24) and IIB (n = 6) cervical squamous cell carcinomas
(Stage), and between tumors without lymph node 
metastasis (n = 21) and with lymph node metastasis 
(n = 9) (LNM). The bars on the right side and left side of
each chromosome ideogram indicate gains and losses, 
respectively. The light gray bars represent the 
chromosomal imbalances detected in stage IB tumors and
those without LNM. The dark gray bars depict 
chromosomal imbalances detected in stage IIB tumors 
and those with LNM. The shortest overlapping regions in
3q11-q22, 3q26-qter and 11q14-q22 (rimmed by boxes)
were significantly more prevalent in tumors 
with LNM than in those without LNM.
together, these observations clearly show that
gain of 3q is an important early genetic event in
cervical carcinogenesis, but it is not a sensitive
enough marker to predict which patients are at
high risk for a poor outcome.
Gain of 3q is also a common genetic aberration
in many other human cancers. Over 100 candidate
genes are present in the shortest region of over-
lap of 3q amplification defined by CGH. Despite
functional assessments of some candidate genes,
including RBP1-RBP2 (on 3q21-q22), CCNL1
(on 3q25.3), hTERC, eIF-5A2, SNO and EVI1 (on
3q26.2), PIK3CA and SCCRO (on 3q26.3), and
p63 and LAMP3 (on 3q27), the precise target(s)
of 3q remains ill-defined. Interestingly, a recent
study found that high LAMP3 expression was sig-
nificantly correlated with the overall survival of
patients with stage I/II cervical cancers,32 imply-
ing that amplification of this gene may likely be
associated with an enhanced metastatic potential.
Once the amplified targeted gene(s) has been
identified, the recent advances in triplex-forming
oligonucleotides, which are used to site-specifically
direct DNA damage in oncogenes, could increase
the range of effectiveness of antitumor nucleosides
in cancer treatment.33 A similar concept could also
be applied to other common gains, including 1q,
5p and 8q detected in this and other studies of
cervical SCC.
Besides loss of 11q and gain of 3q, other com-
mon losses detected in this study also merit ad-
ditional attention. Compared with the common
chromosomal imbalances of gain, losses were
more often suggested to be associated with dis-
ease progression or a poor outcome in other
studies of cervical cancer.7,9 In the present study,
other than 11q, the shortest regions of overlap 
in the common losses were 2q36-qter, 3p14-pter,
6p, 6q23-q25 and 11p. However, there was no
apparent difference in their prevalence in stage
IB and IIB tumors, or in tumors with and with-
out LNM. Notably, these aberrations were found
in some preinvasive lesions in other CGH8,12 or
allelotype34,35 studies, suggesting that they are
unlikely to be rate-limiting in the progression of
cervical cancer.
A number of genes mapping to 2q35-q36, 
including CFLAR, CASP10 and PPP1R7, were
found to be downregulated in some cervical can-
cer cell lines. However, this downregulation could
be reactivated upon exposure to demethylating
agents, suggesting that both genetic and epigenetic
changes play a role in 2q alterations.36 Among the
cancer-related genes on 3p, b-catenin (mapped to
3p21.1) has been excluded from consideration
as a tumor suppressor gene in cervical cancer.37
Notably, FHIT (mapped to 3p14.2) spans the
fragile site FRA3B, which has been suggested as
an integration hot spot for the human papilloma
virus.38 The most important genes on 6p21 could
be the HLA molecules, which are required for 
the immunologic response against human papil-
loma viral infection. The loss of HLA expression
could allow tumors to evade the immune defense
system.39 Loss of 6q23-q25 was present in seven
tumors (23%) in this study, a result comparable
with the 23–31% detected by other allelotype
analyses.15,16 However, genes residing in this 
region have rarely been studied for their poten-
tial as tumor suppressor genes. Loss of 11p was
significantly associated with a poor prognosis 
in stage IB cervical SCC without LNM in a CGH
study,7 but this was not supported by another 
allelotype analysis.26 A number of known tumor
suppressor genes were mapped to 11p, including
WT1, WT2, CDKN1C and TSG 101. The role of
these genes in cervical carcinogenesis is not yet
known.
In conclusion, the present study revealed that
the common chromosomal imbalances in early
stage cervical SCC were gains of 1q, 3q and 8q,
and losses of 2q36-qter, 3p, 6q23-q25 and 11q.
This chromosomal imbalance pattern is largely
consistent with the results of other CGH studies
reported for other populations. However, com-
pared to tumors without LNM, those with LNM
had significantly more prevalent loss of 11q14-
q22 and gains of 3q11-q22 and 3q26-qter. The
results suggest that certain tumor-associated genes
residing on 3q and 11q warrant further investiga-
tion to elucidate their role in the progression of
this disease.
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